Cannonfarah6978

RT and exponential MFR vs. MUAPAMP relationships were calculated for each subject. The level of significance was set at p ≤ 0.05. B terms for the MFR vs. MUAPAMP relationships (p = 0.001, REPL = -4.77 ± 1.82 pps·mV, REP90 = -2.63 ± 1.00 pps·mV) and predicted MFRs for MUs recruited at 40% MVC (p less then 0.001, REPL = 11.14 ± 3.48 pps, REP90 = 18.38 ± 2.60 pps) were greater for REP90 than REPL indicating firing rates were greater during REP90. In addition, larger mean (p = 0.038, REPL = 0.178 ± 0.0668 mV, REP90 = 0.263 ± 0.128 mV) and maximum (p = 0.008, REPL = 0.320 ± 0.127 mV, Rep90 = 0.520 ± 0.234 mV) MUAPAMPS were recorded during REP90 than REPL. Larger MUs were recruited and similar sized MUs maintained greater firing rates during a high-intensity contraction in comparison to a moderate-intensity contraction performed at fatigue. Individuals seeking maximized activation of the MU pool should use high-intensity resistance training paradigms rather than moderate-intensity to fatigue.Davletyarova, K, Vacher, P, Nicolas, M, Kapilevich, LV, and Mourot, L. Associations between heart rate variability-derived indexes and training load repeated measures correlation approach contribution. J Strength Cond Res XX(X) 000-000, 2020-This study aimed to evaluate whether similar associations between indexes derived from heart rate variability (HRV) analyses and training load (TL) could be obtained by using the commonly used Pearson correlation technique and the repeated measures correlation (rmcorr). Fourteen well-trained swimmers (18.5 ± 1.6 years) participated. The training period lasted 4 weeks with a gradual increase in TL. Daily external TL (exTL) and internal TL (inTL) were summed to obtain a weekly TL, and HRV analyses were performed every Saturday morning. During the 4-week period, exTL and inTL increased (p less then 0.05) together with a decrease (p less then 0.05) in heart rate and an increase (p less then 0.05) of cardiac parasympathetic indexes. No significant correlation was found uccasions for multiple individuals, it should constitute a tool for future training monitoring researches based on a repeated-measures protocol.

Following concerns about hormone therapy, postmenopausal women need alternative options to manage menopause-related symptoms and improve their well-being. A 14-week pilot study has shown that supplementation with resveratrol, a phytoestrogen with circulatory benefits, can improve aspects of well-being including chronic pain, which is a common complaint in postmenopausal women. We aimed to confirm these benefits in a larger, long-term study.

The Resveratrol for Healthy Ageing in Women study, a 24-month randomized, double-blind, placebo-controlled, two-period crossover intervention trial of resveratrol supplementation (75 mg BID) was conducted in 125 healthy postmenopausal women to evaluate effects on cognitive performance (results published elsewhere). Aspects of well-being including pain perception, mood and depressive symptoms, menopausal symptoms, sleep quality, and quality of life were assessed with questionnaires as secondary outcomes of the study. Cerebrovascular responsiveness to hypercapnia was measured as a surrogate marker of cerebrovascular function.

Resveratrol supplementation reduced composite pain score (P < 0.001), especially in overweight individuals; this was associated with improvements in cerebrovascular responsiveness to hypercapnia (R = -0.329, P = 0.014). Somatic menopausal symptoms (P = 0.024) and general well-being (P = 0.010) were also improved after resveratrol supplementation.

These results confirm the pilot study finding that resveratrol supplementation can reduce chronic pain in age-related osteoarthritis and improve menopause-related quality of life in postmenopausal women. These improvements are sustained by supplementation for at least 12 months and are associated with enhancement of circulatory function.

ACTRN12616000679482p.

ACTRN12616000679482p.

Menopausal women appear to report a higher risk of Sjögren syndrome (SS). Although Chinese herbal medicines (CHMs) are proven to lower SS risk, the scientific evidence of whether it can lessen the occurrence of SS among menopausal women is limited. This longitudinal cohort study aimed to clarify the relationship between CHMs use and SS risk in menopausal women.

Using a nationwide claims data, we enrolled 31,917 women with first-time diagnosed menopause who simultaneously were free of SS between 2000 and 2007. Among them, we randomly selected 12,757 CHMs users and 12,757 non-CHMs users using propensity scores matching. All participants were followed until the end of 2012 to record SS incidence. The hazard ratio of SS with regard to CHMs use was estimated using the Cox proportional hazards regression model.

In the follow-up period, 589 CHMs users and 644 non-CHMs users developed SS, representing incidence rates of 5.12 and 6.40, respectively, per 1,000 person-years. CHMs use was associated with a 21% lower subsequent risk of SS (adjusted hazard ratio, 0.79; 95% CI, 0.71-0.89). Six commonly prescribed CHMs were discovered to be associated with lower SS risk Ge-Gen-Tang, Zhi-Gan-Cao-Tag, Da-Huang, Ye-Jiao-Teng, Tian-Hua-Fen, and Bo-Zi-Ren.

A statistically significant association was found between CHMs use and lower risk of SS onset in menopausal women, suggesting that CHMs could be considered to integrate it into conventional therapy to reduce subsequent SS risk for menopausal women.

A statistically significant association was found between CHMs use and lower risk of SS onset in menopausal women, suggesting that CHMs could be considered to integrate it into conventional therapy to reduce subsequent SS risk for menopausal women.

To evaluate the success rate of pessary fitting and continuation rate for symptomatic pelvic organ prolapse (POP) patients with a hysterectomy and to explore potential predictors.

In this prospective observational study, 119 symptomatic POP patients with a prior hysterectomy received pessary treatment between April 2015 and February 2019. A successful pessary fitting was defined as a patient who was fitted with a pessary and continued to use it 2 weeks later. Patients with successful pessary fitting were followed until February 2020. Data analysis was performed with t tests, nonparametric tests, chi-square tests, and logistic regression.

The success rate of pessary fitting was 63.2%. A history of POP reconstructive surgery (OR = 2.6, 95% CI 1.0-6.7, P = 0.043) and a short total vaginal length <7.3 cm, (OR = 0.5, 95% CI 0.3-0.9, P = 0.014) were potential risk factors for unsuccessful pessary fitting. Elacridar A total of 78.1% of the patients continued pessary use for a median duration of 26 months. Among patients who discontinued, 75% ceased within 1 year.